1. All applicable plan limitations for coverage of out-of-network care will apply to routine patient care costs in clinical trials; and 2. All utilization management rules and coverage policies that apply to routine care for members not in clinical trials will also apply to routine patient care for members in clinical trials; and 3. Members must meet all applicable plan requirements for prior authorization, registration, and referrals.
4. An approved clinical trial:
a. Is defined as a phase I, phase II, phase III, or phase IV clinical trial conducted in relation to the prevention, detection, or treatment of cancer or another life-threatening disease or condition; and b. Must have a written protocol that describes a scientifically sound study and have been approved by all relevant institutional review boards (IRBs) before participants are enrolled. Providers will not routinely be required to submit documentation about the trial to UHA, but UHA can, at any time, request such documentation to confirm that the clinical trial meets current standards for scientific merit and has the relevant IRB approval(s).
5. A qualified individual is generally a participant or beneficiary who is eligible to participate in an approved clinical trial according to the trial protocol with respect to the treatment of cancer or another life-threatening disease or condition; and either:
a. The referring health care professional is a participating provider and has concluded that the individual's participation in such trial would be appropriate; or b. The participant or beneficiary provides medical and scientific information establishing that the individual's participation in such trial would be appropriate.
B. UHA covers costs of medically necessary treatments for conditions that result as unexpected consequences (complications) A. UHA does not cover the following clinical trial costs:
1. Costs of data collection and record keeping that would not be required but for the clinical trial; and 2. Items and services provided by the trial sponsor without charge; and 3. The experimental intervention itself to include the item, device, or service being tested (except medically necessary Category B investigational devices and promising experimental and investigational interventions in certain clinical trials according to UHA's Emerging Technologies policy (see policy for details)); and 4. Other services to clinical trial participants necessary solely to satisfy data collection needs of the clinical trial (i.e., "protocol-induced costs").
B. UHA will accommodate reasonable laboratory and imaging requests where evidence supports their relative utility in the evaluation of the pertinent disease state. A service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis will not be covered.
A. Prior authorization is not required.
B. This policy may apply to the following codes. Inclusion of a code in the table below does not guarantee that it will be reimbursed. 
